Delcath Systems to Present at Access to Giving Virtual Conference on July 13, 2021 at 3 p.m. ET
07 Juli 2021 - 3:00PM
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology
company focused on the treatment of rare primary and metastatic
cancers of the liver, announced today that the company will present
at Access to Giving Virtual Conference. The presentation will be
given by Delcath’s Chief Executive Officer, Gerard Michel. The
conference is free to all registrants.
Registration DetailsDate:
Tuesday, July 13, 2021Time: 3 p.m. ET Link:
https://access-to-giving.events.issuerdirect.com/signup
To learn more about the event or to schedule a
one-on-one meeting with Delcath’s management, please visit
https://www.accesstogiving.com/ or email
james@haydenir.com.
About Access to Giving Virtual
Conference
Access to Giving is a first-of-its-kind virtual
investor conference where companies will have the opportunity to
present their story and conduct 1x1 meetings with qualified
investors, for charity. Investors will make donations to purchase a
block of meetings to meet with companies.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional
oncology company focused on the treatment of primary and metastatic
liver cancers. Our investigational product, HEPZATO KIT (melphalan
hydrochloride for injection/hepatic delivery system), is designed
to administer high-dose chemotherapy to the liver while controlling
systemic exposure and associated side effects. HEPZATO KIT has not
been approved by the U.S. Food & Drug Administration (FDA) for
sale in the U.S. In Europe, our system is marketed under the trade
name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan
(CHEMOSAT) and has been CE Marked and used at major medical centers
to treat a wide range of cancers of the liver. CHEMOSAT is being
marketed under an exclusive licensing agreement with medac GmbH, a
privately held multi-national pharmaceutical company headquartered
in Germany that specializes in the treatment and diagnosis of
oncological, urological and autoimmune diseases.
Contact
Delcath Investor RelationsEmail:
investorrelations@delcath.com
Hayden IRJames
Carbonara(646)-755-7412james@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024